Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.
Lancet Gastroenterol Hepatol. 2022.
PMID: 35065057
Clinical Trial.